Close Menu

Optra Health OptraGuru 'Digital Genetic Assistant'

Feb 21, 2018

Optra Health has introduced OptraGuru, an Amazon Alexa-compatible "digital genetic assistant" that allows consumers and healthcare professionals alike to verbally query genetic data. Meant to provide context to consumer genetic tests like those from Ancestry.com and 23andMe, OptraGuru puts the Alexa personal digital assistant on the front end of Optra Health's iPhronesis machine-learning platform to help patients, genetic counselors, and bioinformaticians make sense of genetic test results in a conversational manner.

More Like This

Mar 20, 2020

Asuragen Armored RNA Quant SARS-CoV-2 Control

Asuragen is offering an Armored RNA Quant SARS-CoV-2 Control for use in developing assays in response to the COVID-19 pandemic. The new control material targets the SARS-CoV-2 viral nucleocapsid region and, along with the company's new RNAse P construct, aligns with the US Centers for Disease Control and Prevention- and World Health Organization-recommended diagnostic panel. Asuragen said that armored technology encapsulates the in vitro transcribed RNA in a protective protein coat to resist nuclease degradation, enabling its use as RNA extraction, process quality, and positive diagnostic reference controls.

Mar 20, 2020

LGC SeraCare AccuPlex SARS-CoV-2 Reference Material Kit

LGC SeraCare recently launched the AccuPlex SARS-CoV-2 Reference Material Kit, which contains positive reference material targeting the published US Centers for Disease Control and Prevention and World Health Organization consensus sequences, as well as complementary negative reference material targeting the human RNAse P gene. LGC SeraCare said that its kit is superior to "naked" transcribed RNA which does not evaluate the assay extraction step, and safer than heat-treated infectious samples, and are a valuable tool for clinical laboratories seeking to perform assay installation, verification, and performance monitoring.

Mar 20, 2020

Arima Genomics: HiChIP Assay and MAPS Pipeline

Arima Genomics has launched its HiChIP chromatin conformation assay. The assay is built on its Arima-HiC platform and introduces chromatin immunoprecipitation sequencing to provide data on long-range chromatin interactions specifically enriched at genomic locations occupied by proteins of interest.

The firm has also created an optimized version of the Model-based Analysis of Proximity Ligation-Assisted ChIP-seq and HiChIP (MAPS) bioinformatics pipeline to help streamline data analysis.

Mar 20, 2020

Twist Bioscience: SARS-CoV-2/COVID-19 NGS Target Enrichment Panel

Twist Bioscience is offering a research-use-only target enrichment panel for viral detection and characterization of SARS-CoV-2, the virus that causes COVID-19, using next-generation sequencing. The panels, comprising synthetic double-stranded DNA probes covering the entire viral genome, can also be used for environmental monitoring and surveillance. Kits are available in three sizes: 2 reactions, 12 reactions, and 96 reactions.

Mar 20, 2020

Oncocyte DetermaIO

Oncocyte said it has completed CLIA Validation for and launched DetermaIO, previously the Insight Genetics IM Score Test. The test is now available for research use within the biopharmaceutical and academic communities. DetermaIO is a gene expression profile test that evaluates the immune microenvironment in biopsies from cancer patients to identify individuals more or less likely to respond to anti-PD-1/PD-L1 immunotherapy.  The test differentiates itself from other immunotherapy diagnostic tests by having the capability to determine if the immune microenvironment is active or quiescent. DetermaIO has the potential to be used to stratify patients in the more than 3,000 PD-1/PD-L1 ongoing clinical trials that are collectively expected to recruit over 500,000 patients, the company said.

Mar 20, 2020

DNAstack COVID-19 Beacon

DNAstack has released Beacon for SARS-CoV-2, the virus that causes COVID-19, to enable the scientific and medical communities to share and discover knowledge about the genetics of the virus in real time. Beacon, which is available here, will allow information about genetic variants to be shared instantly using software that follows an open international standard, the company said.

Researchers can use the new Beacon to discover sequences with specific genetic mutations and map their geographic and evolutionary origins. The platform integrates derivative data from genetic sequencing libraries such as GISAID and links to Nextstrain pathogen evolution visualizations. 

The COVID-19 Beacon is compliant with the Beacon API, an internationally recognized open-source protocol developed by the Global Alliance for Genomic and Health (GA4GH). The system is deployed on Microsoft Azure, a cloud computing platform with global reach and scalability.

Mar 19, 2020

Paragon Genomics CleanPlex SARS-CoV-2 NGS Panel

Paragon Genomics has launched its CleanPlex SARS-CoV-2 Panel for COVID-19 coronavirus detection, tracking, and research through amplicon-based target enrichment for next-generation sequencing applications. According to the firm, the panel covers the entire genome of the SARS-CoV-2 virus responsible for the global COVID-19 pandemic. Paragon said that the panel's four-step workflow converts viral RNA into sequencing-ready libraries within five hours. Powered by Paragon's CleanPlex's technology, versions of the panel are available for both the Illumina and MGI sequencing platforms. 

Paragon is also offering free consultation for researchers interested in designing custom NGS panels for coronavirus research.

Mar 13, 2020

Bio-Rad Exact Diagnostics SARS CoV-2 Standard

Bio-Rad has launched a standard for SARS-CoV-2 testing through its Exact Diagnostics product line. The standard contains synthetic RNA transcripts of the virus as well as human genomic DNA, enabling labs to test the entire process of a molecular assay, including extraction, amplification, and detection of the virus.

Mar 13, 2020

Microbiologics Synthetic RNA for SARS-CoV-2

Microbiologics is now offering synthetic RNA for SARS-CoV-2 to assist in the efforts to monitor the spread of COVID-19. The material mimics the viral nucleic acid and provides the exact targets specified by the US Centers for Disease Control and Prevention for test development, the company said.

Specifically, it is a 1,044-nucleotide RNA specific for the SARS-CoV-2 N (nucleocapsid) gene. It contains all three markers (N1, N2 and N3) detected by the CDC Real-Time RT PCR Panel for detection of 2019 novel coronavirus. The RNA material assists in the development of diagnostic assays and the evaluation of the performance of nucleic acid tests for determination of the presence of SARS-COV-2.

The RNA is available in two different concentrations: 1x106 and 1x109 genome copies per tube. The material can be shipped within the USA without handling restrictions or permitting requirements. The company noted that permits may be required outside the USA and interested parties should check with local authorities.

Mar 12, 2020

Twist Bioscience Synthetic SARS-CoV-2 RNA Controls

Twist Bioscience has made two synthetic SARS-CoV-2 RNA controls available for use in quality control in the development and validation of next-generation sequencing- and reverse-transcription PCR-based tests.

The sequence-verified controls are designed to cover the full viral genome of two specific virus variants: MN908947.3, considered the reference genome, isolated from a patient in Wuhan, China, and MT007544.1, isolated from a patient in Australia.

Twist noted that customers purchasing synthetic controls are subject to the firm's biosecurity screening protocols.

Mar 11, 2020

ZeptoMetrix NATtrol SARS-CoV-2 Recombinant Construct

ZeptoMetrix has released its newly inactivated and non-infectious NATtrol SARS-CoV-2 Recombinant construct for laboratory quality control and test validation.

This non-infectious quality control incorporates a recombinant construct associated with targeted detection regions of the virus that may be used in the development of molecular assays designed to detect SARS-CoV-2. It can also be used in BSL-2 facilities in place of the live virus, as non-infectious, external quality controls for assays developed to detect SARS-CoV-2, the company said.

Mar 10, 2020

Fluidigm AccuLift Laser Capture Microdissection System

Fluidigm has launched the AccuLift Laser Capture Microdissection System, which enables precise and efficient capture of individual cells or larger tissue regions from frozen and FFPE tissue sections for DNA, RNA, and protein biomarker analysis using sequencing, real-time PCR, or mass spectrometry. Fluidigm said that it collaborated with Lance Liotta, codirector of the Center for Applied Proteomics and Molecular Medicine at George Mason University, to develop the AccuLift product portfolio. The new system features a patent-pending design including a high-precision stage and uniquely aligned IR and UV lasers. It also features a new capture method developed in Liotta's laboratory that increases the efficiency of cellular capture and extraction.

Mar 10, 2020

BioDynami NGS RNA Library Prep Kit

BioDynami has released a new sequencing library preparation product called NGS RNA Library Prep Kit. It takes 3 ng to 100 ng of purified RNA as input material, is compatible with different types of indexes for multiplexing, and is designed for Illumina sequencing. The workflow takes 2 hours in total, with 10 minutes of hands-on time.

Mar 09, 2020

IsoPlexis CodePlex Secretome and Single-Cell Innate & Myeloid Solution

IsoPlexis has released two new products for use with its IsoLight cellular proteomics instrument.

CodePlex Secretome is a fully automated approach to obtaining highly multiplexed bulk cytokine data that requires five minutes of hands-on time for sample loading. CodePlex Secretome multiplexes more than 30 cytokines, and is modular so users can simultaneously examine as few as eight samples or as many as 64.

The new Single-Cell Innate & Myeloid solution detects the functional single-cell differences from innate and myeloid cells by identifying what each cell secretes in a highly multiplexed (32-plus cytokines) manner to reveal the sources of cellular difference through functional phenotyping. It joins other IsoLight single-cell chip applications which allow researchers to visualize single-cell-level data and pinpoint biological drivers.

Mar 06, 2020

Biogazelle HTPathwaySeq and HTTargetSeq

Belgian CRO Biogazelle has launhced HTPathwaySeq and HTTargetSeq RNA sequencing and data-analysis services. HTPathwaySeq generates in-depth information on drug mode of action, highlights molecular similarities between compounds, and reveals potential compound-induced toxicities, all of which help provide critical data for candidate prioritization in drug development.
 
HTTargetSeq supports the development of RNA-targeting oligonucleotides such as short interfering RNAs (siRNA) and antisense oligonucleotides (ASO). The service accurately identifies off-target genes, which the company noted is important for the anticipation of safety issues and potential repurposing of off-target genes as novel therapeutic targets.
 
Both services are performed directly on cell lysates from 96-well culture plates, and data interpretation results are shared through Savana, Biogazelle’s proprietary visualization app.

Master's and doctoral students in the UK call on funding groups to extend their grants for the duration of the disruption caused by the COVID-19 outbreak, the Guardian reports.

Squid can make edits to their RNA within the cytoplasm of their axons, Science News reports.

The Chan Zuckerberg Initiative is putting $25 million toward COVID-19 treatment research, according to the Verge.

In Science this week: researchers engineer version of Cas9 that is nearly PAM-less, and more.

Mar
30
Sponsored by
GenomeWeb/ABRF

This webinar features two speakers who will discuss novel computational approaches to optimize sequencing workflows on Oxford Nanopore sequencing platforms.

May
06
Sponsored by
Isoplexis

This webinar will discuss the application of single-cell proteomics and immune-imaging in adoptive cell therapy (ACT) for cancer.